FibroGen, Inc.

BMV:FGEN * Stock Report

Market Cap: Mex$772.5m

FibroGen Future Growth

Future criteria checks 0/6

FibroGen's revenue is forecast to decline at 4.4% per annum while its annual earnings are expected to grow at 27.1% per year. EPS is expected to grow by 38.8% per annum.

Key information

27.1%

Earnings growth rate

38.8%

EPS growth rate

Biotechs earnings growth0%
Revenue growth rate-4.4%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BMV:FGEN * - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026161-77N/AN/A2
12/31/2025150-90N/AN/A2
12/31/2024174-90N/AN/A2
6/30/2024174-168-203-202N/A
3/31/2024167-240-275-273N/A
12/31/2023148-284-318-315N/A
9/30/2023155-294-352-349N/A
6/30/2023131-322-319-317N/A
3/31/2023116-307-242-239N/A
12/31/2022141-294-185-146N/A
9/30/2022123-362-188-148N/A
6/30/2022263-220-118-52N/A
3/31/2022258-281-112-46N/A
12/31/2021235-290-112-82N/A
9/30/2021284-215-66-34N/A
6/30/2021172-231-85-80N/A
3/31/2021190-1839296N/A
12/31/2020176-1897882N/A
9/30/2020119-2294044N/A
6/30/2020108-3111318N/A
3/31/2020257-110-166-161N/A
12/31/2019257-77-84-79N/A
9/30/201935742-58-51N/A
6/30/201935349-22-15N/A
3/31/2019205-90-28-22N/A
12/31/2018213-86-84-76N/A
9/30/2018136-141-68-60N/A
6/30/2018147-123-97-87N/A
3/31/2018133-132N/A-71N/A
12/31/2017131-121N/A-67N/A
9/30/2017132-121N/A-84N/A
6/30/2017122-121N/A-67N/A
3/31/2017181-64N/A-3N/A
12/31/2016183-58N/A7N/A
9/30/2016172-79N/A-14N/A
6/30/2016162-100N/A-50N/A
3/31/2016193-67N/A6N/A
12/31/2015181-86N/A-19N/A
9/30/2015172-85N/A-3N/A
6/30/2015167-79N/A4N/A
3/31/2015136-98N/A-4N/A
12/31/2014138-60N/A22N/A
9/30/2014134-24N/A24N/A
6/30/201419143N/A128N/A
3/31/2014117-5N/A30N/A
12/31/2013102-15N/A26N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FGEN * is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FGEN * is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FGEN * is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FGEN *'s revenue is expected to decline over the next 3 years (-4.4% per year).

High Growth Revenue: FGEN *'s revenue is forecast to decline over the next 3 years (-4.4% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FGEN *'s Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y